Life Medical Sciences' Repel
This article was originally published in The Gray Sheet
Pivotal trial in the U.S. employing the bioresorbable copolymer gel for prevention or reduction of adhesions following gynecological surgery will include 140 patients at roughly 14 sites and is slated to begin in the third quarter. Edison, New Jersey-based LMS announced investigational device exemption clearance April 30. Pilot study data show the product to be twice as effective in reducing adhesion formation compared to the control of standard surgical treatment; the device was particularly effective in treating adhesion formation on the posterior surface of the uterus ("The Gray Sheet" Dec. 22, In Brief). LMS is conducting a pilot study for Repel-CV for prevention of adhesions following cardiovascular surgery ("The Gray Sheet" March 30, p. 24) and has completed preclinical studies on Resolve, a bioresorbable viscous solution for reducing post-operative adhesions in gynecological and general abdominal surgeries. Preclinical studies are ongoing for Relieve gel for orthopedic use
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.